Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Global epidemiology of use of and disparities in caesarean sections

    Research output: Contribution to journalComment/debateResearchpeer-review

  2. Populations, decreasing fertility, and reproductive health

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Bariatric surgery-which procedure is the optimal choice?

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Screening for abdominal aortic aneurysm - Authors' reply

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Oxygenation targets in acutely ill patients: still a matter of debate

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Early versus later treatment start in multiple sclerosis: a register-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Alasdair J Coles
  • Cary L Twyman
  • Douglas L Arnold
  • Jeffrey A Cohen
  • Christian Confavreux
  • Edward J Fox
  • Hans-Peter Hartung
  • Eva Havrdova
  • Krzysztof W Selmaj
  • Howard L Weiner
  • Tamara Miller
  • Elizabeth Fisher
  • Rupert Sandbrink
  • Stephen L Lake
  • David H Margolin
  • Pedro Oyuela
  • Michael A Panzara
  • D Alastair S Compston
  • CARE-MS II investigators
  • Per Soelberg Sørensen
View graph of relations
The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment.
Original languageEnglish
JournalLancet
Volume380
Issue number9856
Pages (from-to)1829-39
Number of pages11
ISSN0140-6736
DOIs
Publication statusPublished - 2012

    Research areas

  • Adjuvants, Immunologic, Administration, Cutaneous, Adolescent, Adult, Antibodies, Monoclonal, Humanized, Female, Humans, Immunosuppressive Agents, Infusions, Intravenous, Male, Middle Aged, Multiple Sclerosis, Relapsing-Remitting, Peptides, Recurrence, Treatment Outcome, Young Adult

ID: 36727783